Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）

Launched by BEIJING TSINGHUA CHANG GUNG HOSPITAL · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new oral medicine called oteseconazole, which is being tested to treat severe vulvovaginal candidiasis (VVC), a common yeast infection that affects the vaginal area. The goal of the study is to see how well oteseconazole works and how safe it is for women who have this condition. The trial will observe patients in real-world settings across several centers and will include both looking back at past cases and following new patients over time.

Women who are 18 years or older with significant symptoms of VVC (such as itching, burning, or discharge) and a certain severity score may be eligible to join. Participants will be those planning to use oteseconazole alone or with other treatments. Pregnant or breastfeeding women, or those involved in other clinical studies, will not be included. If you join, you can expect regular monitoring to understand how the medicine is helping and to check for any side effects. This study is not yet open for new participants but aims to provide important information about a promising new treatment option for severe yeast infections.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years old, female; vulvovaginal signs and symptoms (VSS) score ≥7; Plan to use oteseconazole monotherapy or combination therapy
• Exclusion Criteria:
• • Evidence has shown that the patient whohas been pregnant or lactating; Patients who are participating in or planning to participate in other interventional clinical studies; Other situations determined by the researcher as unsuitable for inclusion in the study